Phase-II reactions - Synthetic reactions

PHASE - II REACTIONS

  • Conjugation of a functional group to the drug or its metabolite to make it water soluble
  • The presence of –OH, -COOH, -NH2, -SH groups favour formation of conjugates (these groups are added to (or) exposed in Phase I)

Glucuronidation

  • The most important reaction – most drugs incl. endogenous steroids and bile pigments undergo this reaction.
  • Glucuronide conjugation takes place in microsomes.
  • The source of glucuronide is UDPGA through glucuronyl transferase.
  • The product is highly soluble and is excreted by urine (if MW<300 – 500) or via bile ( if >500)
  • Beta -glucuronidase in intestine may liberate the active drug which is again reabsorbed and undergoes enterohepatic recirculation which leads to longer duration of action of the drug

Sulfate conjugation (non-microsomal)

  • Forms ethereal sulfates - eg. Phenols, acetaminophen, morphine and endogenous heparin, chondroitin and some steroids

Acetylation (non microsomal)

  • Acetylates are formed eg. Sulphonamides --- acetyl CoA is the donor
  • Acetylates are poorly soluble in water and lipid and are likely to cause crystalluria

Methylation (non-microsomal)

  • Adds methyl radicals – The aminoacids methionine and cysteine are the donors
  • eg. Histamine, adrenaline, sex steroids

Glycine conjugation (non-microsomal)

  • Not a major pathway, eg. Salicylates

Glutathione conjugation

  • Not a major pathway – forms mercapturic acids – important for removal of toxic radicals (superoxides, epoxides and toxic intermediates)

Ribonucleoside / Ribonucleotide synthesis

  • These reactions are important for the activation of purine and pyrimidine antimetbolites used in cancer therapy
  • Drug conjugates were once believed to represent terminal inactivation events and as such have been viewed as “true detoxification” reactions.
  • However, this concept must be modified, since it is now known that certain conjugation reactions may lead to the formation of reactive species responsible for the hepatotoxicity of the drug.
Last modified: Wednesday, 25 April 2012, 5:56 AM